
Charles Adler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2895550/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 2015, 30, 1591-1601.	2.2	4,389
2	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: <i>Movement</i> Disorder Society Task Force guidelines. Movement Disorders, 2012, 27, 349-356.	2.2	1,908
3	MDS research criteria for prodromal Parkinson's disease. Movement Disorders, 2015, 30, 1600-1611.	2.2	1,033
4	Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain, 2013, 136, 2419-2431.	3.7	965
5	Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathologica, 2010, 119, 689-702.	3.9	758
6	MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PDâ€MCI. Movement Disorders, 2011, 26, 1814-1824.	2.2	649
7	Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathologica, 2009, 117, 613-634.	3.9	553
8	Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A–resistant cervical dystonia. Neurology, 1999, 53, 1431-1431.	1.5	427
9	Low clinical diagnostic accuracy of early vs advanced Parkinson disease. Neurology, 2014, 83, 406-412.	1.5	395
10	Defining mild cognitive impairment in Parkinson's disease. Movement Disorders, 2007, 22, 1272-1277.	2.2	388
11	<scp>A</scp> rizona <scp>S</scp> tudy of <scp>A</scp> ging and <scp>N</scp> eurodegenerative <scp>D</scp> isorders and <scp>B</scp> rain and <scp>B</scp> ody <scp>D</scp> onation <scp>P</scp> rogram. Neuropathology, 2015, 35, 354-389.	0.7	336
12	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	4.5	312
13	The neurobiological basis of cognitive impairment in Parkinson's disease. Movement Disorders, 2014, 29, 634-650.	2.2	282
14	Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Movement Disorders, 2003, 18, 287-293.	2.2	265
15	A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology, 2001, 56, 1523-1528.	1.5	207
16	The Montreal Cognitive Assessment and the Mini-Mental State Examination as Screening Instruments for Cognitive Impairment: Item Analyses and Threshold Scores. Dementia and Geriatric Cognitive Disorders, 2011, 31, 126-131.	0.7	200
17	Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathologica, 2009, 117, 169-74.	3.9	193
18	Pathologic findings in prospectively ascertained essential tremor subjects. Neurology, 2008, 70, 1452-1455.	1.5	191

#	Article	IF	CITATIONS
19	Parkinson Disease With Dementia. Alzheimer Disease and Associated Disorders, 2009, 23, 295-297.	0.6	183
20	Quantitative EEG as a predictive biomarker for Parkinson disease dementia. Neurology, 2011, 77, 118-124.	1.5	178
21	Neuropathological basis of nonmotor manifestations of Parkinson's disease. Movement Disorders, 2016, 31, 1114-1119.	2.2	173
22	Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathologica, 2012, 124, 665-680.	3.9	169
23	Tau Positron-Emission Tomography in Former National Football League Players. New England Journal of Medicine, 2019, 380, 1716-1725.	13.9	165
24	Does Parkinson's disease start in the gut?. Acta Neuropathologica, 2018, 135, 1-12.	3.9	161
25	Evaluation of α-synuclein immunohistochemical methods used by invited experts. Acta Neuropathologica, 2008, 116, 277-288.	3.9	157
26	National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. Neurology, 2021, 96, 848-863.	1.5	149
27	Nonmotor complications in Parkinson's disease. Movement Disorders, 2005, 20, S23-S29.	2.2	140
28	Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry. Scientific Reports, 2014, 4, 5797.	1.6	133
29	REM sleep behavior disorder and neuropathology in Parkinson's disease. Movement Disorders, 2015, 30, 1413-1417.	2.2	128
30	Parkinson Disease Affects Peripheral Sensory Nerves in the Pharynx. Journal of Neuropathology and Experimental Neurology, 2013, 72, 614-623.	0.9	123
31	Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. Acta Neuropathologica, 2016, 131, 393-409.	3.9	123
32	Sleep issues in Parkinson's disease. Neurology, 2005, 64, S12-20.	1.5	121
33	Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains. Experimental Neurology, 2013, 240, 190-204.	2.0	120
34	Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology, 2014, 82, 858-864.	1.5	120
35	Altered Pharyngeal Muscles in Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2012, 71, 520-530.	0.9	118
36	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. Movement Disorders, 2017, 32, 1056-1065.	2.2	117

#	Article	IF	CITATIONS
37	Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathologica, 2008, 115, 445-451.	3.9	116
38	Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurology, The, 2021, 20, 671-684.	4.9	116
39	Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects. Neuroscience Letters, 2014, 571, 34-38.	1.0	115
40	Movement disorder society criteria for clinically established early Parkinson's disease. Movement Disorders, 2018, 33, 1643-1646.	2.2	114
41	Phosphorylated αâ€synuclein in the retina is a biomarker of Parkinson's disease pathology severity. Movement Disorders, 2018, 33, 1315-1324.	2.2	113
42	Alpha-Synuclein Pathology and Axonal Degeneration of the Peripheral Motor Nerves Innervating Pharyngeal Muscles in Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2013, 72, 119-129.	0.9	112
43	Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, 348-354.	1.1	110
44	Incidental Lewy body disease: Clinical comparison to a control cohort. Movement Disorders, 2010, 25, 642-646.	2.2	109
45	Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism and Related Disorders, 2014, 20, 525-529.	1.1	107
46	Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2013, 72, 130-136.	0.9	106
47	Hemifacial spasm: Evaluation by magnetic resonance imaging and magnetic resonance tomographic angiography. Annals of Neurology, 1992, 32, 502-506.	2.8	99
48	Ropinirole for restless legs syndrome. Neurology, 2004, 62, 1405-1407.	1.5	98
49	Botulinum Toxin Type A for Treating Voice Tremor. Archives of Neurology, 2004, 61, 1416.	4.9	91
50	In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease. Neurology, 2020, 95, e1267-e1284.	1.5	91
51	Parkinson disease and incidental Lewy body disease. Neurology, 2015, 85, 1670-1679.	1.5	88
52	Blinded <scp>RTâ€QuIC</scp> Analysis of <scp>αâ€Synuclein</scp> Biomarker in Skin Tissue From Parkinson's Disease Patients. Movement Disorders, 2020, 35, 2230-2239.	2.2	88
53	Syllabic strength and lexical boundary decisions in the perception of hypokinetic dysarthric speech. Journal of the Acoustical Society of America, 1998, 104, 2457-2466.	0.5	84
54	The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurology, The, 2016, 15, 546-548.	4.9	82

#	Article	IF	CITATIONS
55	Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition. Journal of Neuropathology and Experimental Neurology, 2016, 75, 748-754.	0.9	82
56	The ???Yips??? in Golf. Sports Medicine, 2003, 33, 13-31.	3.1	80
57	α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy. Acta Neuropathologica, 2021, 142, 495-511.	3.9	80
58	Graph theory network function in Parkinson's disease assessed with electroencephalography. Clinical Neurophysiology, 2016, 127, 2228-2236.	0.7	79
59	Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease. Nature Neuroscience, 2018, 21, 1482-1492.	7.1	79
60	Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathologica, 2010, 120, 827-828.	3.9	75
61	Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome. Parkinsonism and Related Disorders, 2011, 17, 456-458.	1.1	73
62	The Search for a Peripheral Biopsy Indicator of α-Synuclein Pathology for Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2017, 76, nlw103.	0.9	73
63	Abnormal co-contraction in yips-affected but not unaffected golfers: Evidence for focal dystonia. Neurology, 2005, 64, 1813-1814.	1.5	71
64	Importance of low diagnostic Accuracy for early Parkinson's disease. Movement Disorders, 2018, 33, 1551-1554.	2.2	70
65	Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 1260-1262.	1.1	68
66	Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson's Disease and Control Subjects. Journal of Parkinson's Disease, 2016, 6, 761-770.	1.5	68
67	Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). Journal of the Neurological Sciences, 2015, 349, 84-93.	0.3	67
68	Peripheral <scp>S</scp> ynucleinopathy in <scp>E</scp> arly <scp>P</scp> arkinson's <scp>D</scp> isease: <scp>S</scp> ubmandibular <scp>G</scp> land <scp>N</scp> eedle <scp>B</scp> iopsy <scp>F</scp> indings. Movement Disorders, 2016, 31, 250-256.	2.2	66
69	Clinicopathological Outcomes of Prospectively Followed Normal Elderly Brain Bank Volunteers. Journal of Neuropathology and Experimental Neurology, 2014, 73, 244-252.	0.9	65
70	Biochemical Increase in Phosphorylated Alphaâ€Synuclein Precedes Histopathology of Lewyâ€Type Synucleinopathies. Brain Pathology, 2012, 22, 745-756.	2.1	62
71	Perioperative use of botulinum toxin for movement disorder-induced cervical spine disease. Movement Disorders, 1996, 11, 79-81.	2.2	60
72	Simplified conversion method for unified Parkinson's disease rating scale motor examinations. Movement Disorders, 2015, 30, 1967-1970.	2.2	59

#	Article	IF	CITATIONS
73	Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders. Journal of Parkinson's Disease, 2016, 6, 153-163.	1.5	58
74	Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurological Research, 2012, 34, 669-676.	0.6	57
75	Lexical boundary error analysis in hypokinetic and ataxic dysarthria. Journal of the Acoustical Society of America, 2000, 107, 3415-3424.	0.5	56
76	Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson's disease. Acta Neuropathologica Communications, 2018, 6, 90.	2.4	56
77	Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 1089-1093.	1.1	54
78	Essential tremor and Parkinson's disease: Lack of a link. Movement Disorders, 2011, 26, 372-377.	2.2	53
79	Dopaminergic Retinal Cell Loss and Visual Dysfunction in Parkinson Disease. Annals of Neurology, 2020, 88, 893-906.	2.8	52
80	The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease. Biomarkers in Medicine, 2017, 11, 359-368.	0.6	50
81	Brain biochemistry in autopsied patients with essential tremor. Movement Disorders, 2012, 27, 113-117.	2.2	48
82	Essential tremor is not a neurodegenerative disease. Neurodegenerative Disease Management, 2012, 2, 259-268.	1.2	47
83	Consensus-Based Attributes for Identifying Patients With Spasmodic Dysphonia and Other Voice Disorders. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 657.	1.2	47
84	Knowledge gaps and research recommendations for essential tremor. Parkinsonism and Related Disorders, 2016, 33, 27-35.	1.1	46
85	Dystonia and Tremor. Neurology, 2021, 96, e563-e574.	1.5	46
86	The Mayo Clinic Arizona Spasmodic Dysphonia Experience. Annals of Otology, Rhinology and Laryngology, 2015, 124, 859-863.	0.6	45
87	Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging. Journal of Neuropathology and Experimental Neurology, 2019, 78, 891-899.	0.9	44
88	Parkinson's Disease and Sleep. Neurologic Clinics, 2005, 23, 1187-1208.	0.8	43
89	Olfaction in the Elderly: A Cross-Sectional Analysis Comparing Parkinson's Disease with Controls and Other Disorders. International Journal of Neuroscience, 2010, 120, 36-39.	0.8	43
90	Neuropathological findings of PSP in the elderly without clinical PSP: Possible incidental PSP?. Parkinsonism and Related Disorders, 2011, 17, 365-371.	1.1	43

#	Article	IF	CITATIONS
91	Abolishing the 1â€year rule: How much evidence will be enough?. Movement Disorders, 2016, 31, 1623-1627.	2.2	43
92	Spasmodic Dysphonia: A Review. Part 1: Pathogenic Factors. Otolaryngology - Head and Neck Surgery, 2017, 157, 551-557.	1.1	43
93	Vagus Nerve and Stomach Synucleinopathy in Parkinson's Disease, Incidental Lewy Body Disease, and Normal Elderly Subjects: Evidence Against the "Body-First―Hypothesis. Journal of Parkinson's Disease, 2021, 11, 1833-1843.	1.5	41
94	Are there differences in cerebral white matter lesion burdens between Parkinson's disease patients with or without dementia?. Acta Neuropathologica, 2010, 119, 147-149.	3.9	40
95	Differential spectral quantitative electroencephalography patterns between control and Parkinson's disease cohorts. European Journal of Neurology, 2016, 23, 387-392.	1.7	40
96	Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers. BMC Neurology, 2018, 18, 125.	0.8	39
97	Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. Journal of Parkinson's Disease, 2012, 2, 57-65.	1.5	38
98	Spasmodic Dysphonia: A Review. Part 2: Characterization of Pathophysiology. Otolaryngology - Head and Neck Surgery, 2017, 157, 558-564.	1.1	38
99	Relevance of motor complications in Parkinson's disease. Neurology, 2002, 58, S51-6.	1.5	38
100	Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. Movement Disorders, 2004, 19, 1075-1079.	2.2	37
101	Advances in Biomarker Research in Parkinson's Disease. Current Neurology and Neuroscience Reports, 2016, 16, 7.	2.0	37
102	Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism and Related Disorders, 2002, 9, 103-110.	1.1	36
103	Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinson's Disease Patients. Dysphagia, 2015, 30, 404-417.	1.0	36
104	Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment. BMC Neurology, 2015, 15, 146.	0.8	36
105	Correlation of Clinical Features With Argyrophilic Grains at Autopsy. Alzheimer Disease and Associated Disorders, 2009, 23, 229-233.	0.6	35
106	Are the yips a taskâ€specific dystonia or "golfer's crampâ€?. Movement Disorders, 2011, 26, 1993-1996.	2.2	34
107	Abnormal Visual Contrast Acuity in Parkinson's Disease. Journal of Parkinson's Disease, 2015, 5, 125-130.	1.5	33
108	Tau immunoreactivity in peripheral tissues of human aging and select tauopathies. Neuroscience Letters, 2019, 696, 132-139.	1.0	33

#	Article	IF	CITATIONS
109	Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). Journal of Neuropathology and Experimental Neurology, 2018, 77, 793-802.	0.9	32
110	Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study. Acta Neurologica Scandinavica, 2019, 139, 76-81.	1.0	32
111	Risk of Parkinson's disease dementia related to level I MDS PDâ€MCI. Movement Disorders, 2019, 34, 430-435.	2.2	32
112	Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.5	31
113	Impact of Cervical Dystonia on Work Productivity: An Analysis From a Patient Registry. Movement Disorders Clinical Practice, 2016, 3, 130-138.	0.8	31
114	Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. PLoS ONE, 2019, 14, e0217566.	1.1	31
115	Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. Acta Neuropathologica Communications, 2022, 10, .	2.4	31
116	Slowing of number naming speed by King–Devick Test in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 226-229.	1.1	30
117	Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry. Journal of the Neurological Sciences, 2017, 376, 84-90.	0.3	30
118	Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project. Alzheimer's Research and Therapy, 2021, 13, 136.	3.0	30
119	Pathology in essential tremor. Parkinsonism and Related Disorders, 2012, 18, S135-S137.	1.1	29
120	An Update on the Neurologic Applications of Botulinum Toxins. Current Neurology and Neuroscience Reports, 2010, 10, 338-344.	2.0	27
121	Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's disease. Movement Disorders, 2016, 31, 1012-1019.	2.2	27
122	GBA mutations in Parkinson disease: earlier death but similar neuropathological features. European Journal of Neurology, 2017, 24, 1363-1368.	1.7	27
123	Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia. PLoS ONE, 2020, 15, e0231720.	1.1	27
124	Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimer's pathology not α-synuclein pathology. Neurobiology of Aging, 2017, 54, 175-186.	1.5	26
125	Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurology, 2011, 11, 140.	0.8	25
126	Next-generation profiling to identify the molecular etiology of Parkinson dementia. Neurology: Genetics, 2016, 2, e75.	0.9	25

#	Article	IF	CITATIONS
127	The patient with Parkinson?s disease: Part I?Treating the motor symptoms; Part II?Treating the nonmotor symptoms. Journal of the American Academy of Nurse Practitioners, 2007, 19, 179-197.	1.4	23
128	SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19. Journal of Neuropathology and Experimental Neurology, 2022, 81, 666-695.	0.9	22
129	The Yips: Methods to Identify Golfers with a Dystonic Etiology/Golfer's Cramp. Medicine and Science in Sports and Exercise, 2018, 50, 2226-2230.	0.2	21
130	Premotor Symptoms and Early Diagnosis of Parkinson's Disease. International Journal of Neuroscience, 2011, 121, 3-8.	0.8	20
131	Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation. Movement Disorders, 2017, 32, 274-277.	2.2	20
132	Electrophysiological observations in hereditary parkinsonism-dementia with Lewy body pathology. Movement Disorders, 2000, 15, 140-145.	2.2	19
133	Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis. Parkinsonism and Related Disorders, 2018, 55, 92-96.	1.1	19
134	Association of probable REM sleep behavior disorder with pathology and years of contact sports play in chronic traumatic encephalopathy. Acta Neuropathologica, 2020, 140, 851-862.	3.9	19
135	DIFFERENTIAL DIAGNOSIS OF PARKINSON'S DISEASE. Medical Clinics of North America, 1999, 83, 349-367.	1.1	18
136	Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia. Movement Disorders, 2002, 17, 158-161.	2.2	18
137	Essential Tremor in the Elderly and Risk for Dementia. Journal of Neurodegenerative Diseases, 2014, 2014, 1-5.	1.1	17
138	Weight Loss in Parkinson's Disease: No Evidence for Role of Small Intestinal Bacterial Overgrowth. Journal of Parkinson's Disease, 2018, 8, 571-581.	1.5	17
139	Strategies for controlling dystonia. Postgraduate Medicine, 2000, 108, 151-160.	0.9	16
140	Parkinson's disease, cortical dysfunction, and alphaâ€synuclein. Movement Disorders, 2011, 26, 1436-1442.	2.2	16
141	Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4). Journal of Parkinson's Disease, 2018, 8, 517-527.	1.5	16
142	Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease. Neurology: Clinical Practice, 2021, 11, e414-e421.	0.8	16
143	Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Openâ€label ADSâ€5102. Movement Disorders Clinical Practice, 2018, 5, 183-190.	0.8	15
144	Feasibility of repeat and bilateral submandibular gland needle biopsies in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 68, 69-72.	1.1	14

#	Article	IF	CITATIONS
145	Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. Journal of the Neurological Sciences, 2019, 405, 116413.	0.3	14
146	Neuropathological Findings in Parkinson's Disease With Mild Cognitive Impairment. Movement Disorders, 2020, 35, 845-850.	2.2	14
147	Quantitative Appraisal of Ventricular Cerebrospinal Fluid Biomarkers in Neuropathologically Diagnosed Parkinson's Disease Cases Lacking Alzheimer's Disease Pathology. Biomarker Insights, 2013, 8, BMI.S11422.	1.0	13
148	Effect of olfactory bulb pathology on olfactory function in normal aging. Brain Pathology, 2022, 32, e13075.	2.1	13
149	Unawareness of Hyposmia in Elderly People With and Without Parkinson's Disease. Movement Disorders Clinical Practice, 2016, 3, 43-47.	0.8	12
150	Improved diagnosis of Parkinson's disease from a detailed olfactory phenotype. Annals of Clinical and Translational Neurology, 2017, 4, 714-721.	1.7	12
151	Regional neuropathology distribution and verbal fluency impairments in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 65, 73-78.	1.1	12
152	Co-Existence of tau and α-synuclein pathology in fetal graft tissue at autopsy: A case report. Parkinsonism and Related Disorders, 2020, 71, 36-39.	1.1	11
153	Nonâ€motor phenotypic subgroups in adultâ€onset idiopathic, isolated, focal cervical dystonia. Brain and Behavior, 2021, 11, e2292.	1.0	11
154	Level I <scp>PDâ€MCI</scp> Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia. Movement Disorders Clinical Practice, 2022, 9, 479-483.	0.8	11
155	Incidental Lewy body disease: Electrophysiological findings suggesting pre-clinical Lewy body disorders. Clinical Neurophysiology, 2011, 122, 2426-2432.	0.7	10
156	Movement Disorders and Sleep. Neurologic Clinics, 2012, 30, 1345-1358.	0.8	9
157	Hypermethylation of Synphilin-1, Alpha-Synuclein-Interacting Protein (SNCAIP) Gene in the Cerebral Cortex of Patients with Sporadic Parkinson's Disease. Brain Sciences, 2017, 7, 74.	1.1	9
158	Disease Duration Influences Gene Expression in Neuromelanin-Positive Cells From Parkinson's Disease Patients. Frontiers in Molecular Neuroscience, 2021, 14, 763777.	1.4	9
159	Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. CNS Spectrums, 2018, 23, 402-413.	0.7	8
160	Antemortem detection of Parkinson's disease pathology in peripheral biopsies using artificial intelligence. Acta Neuropathologica Communications, 2022, 10, 21.	2.4	8
161	Synuclein-One study: skin biopsy detection of phosphorylated α-synuclein for diagnosis of synucleinopathies. Biomarkers in Medicine, 2022, 16, 499-509.	0.6	8
162	Cardiac sympathetic denervation and synucleinopathy in Alzheimer's disease with brain Lewy body disease. Brain Communications, 2020, 2, fcaa004.	1.5	7

#	Article	IF	CITATIONS
163	Olfaction in Neuropathologically Defined Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 1700-1704.	2.2	7
164	Restless Legs Syndrome Shows Increased Silent Postmortem Cerebral Microvascular Disease With Gliosis. Journal of the American Heart Association, 2021, 10, e019627.	1.6	7
165	Prevalence of hippocampal sclerosis in a clinicopathologically characterized cohort. Clinical and Experimental Medical Sciences, 2013, 1, 317-327.	0.4	7
166	Cerebellar ataxia, dystonia, and tremor within a family: Variable phenotypes of a single genetic disorder?. Movement Disorders, 2004, 9, 155-160.	2.2	6
167	Variability of diffuse plaques and amyloid angiopathy in Parkinson's disease with mild cognitive impairment. Acta Neuropathologica, 2010, 120, 831-831.	3.9	6
168	Lewy bodies in essential tremor are no different than in controls. Parkinsonism and Related Disorders, 2016, 23, 106-107.	1.1	6
169	Contrast Acuity With Different Colors in Parkinson's Disease. Movement Disorders Clinical Practice, 2019, 6, 672-677.	0.8	6
170	It's tricky: Rating alleviating maneuvers in cervical dystonia. Journal of the Neurological Sciences, 2020, 419, 117205.	0.3	6
171	Perioperative use of botulinum toxins. Toxicon, 2009, 54, 654-657.	0.8	5
172	Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease. Movement Disorders, 2018, 33, 652-654.	2.2	5
173	Association Between Pathology and Electroencephalographic Activity in Parkinson's Disease. Clinical EEG and Neuroscience, 2018, 49, 321-327.	0.9	5
174	Olfactory Bulb Amyloid-Î ² Correlates With Brain Thal Amyloid Phase and Severity of Cognitive Impairment. Journal of Neuropathology and Experimental Neurology, 2022, 81, 643-649.	0.9	4
175	Brain Lewy-Type Synucleinopathy Density Is Associated with a Lower Prevalence of Atherosclerotic Cardiovascular Disease Risk Factors in Patients with Parkinson's Disease1. Journal of Parkinson's Disease, 2019, 9, 543-552.	1.5	3
176	Dystonic Golfer's cramp: Pilot study of propranolol and looking at the hole. Parkinsonism and Related Disorders, 2020, 80, 108-112.	1.1	3
177	Essential tremor and cognitive decline. Parkinsonism and Related Disorders, 2021, 83, 125.	1.1	3
178	An initial exploration of the convergent and ecological validity of the UDS 3.0 neuropsychological battery in Parkinson's Disease. Journal of Clinical and Experimental Neuropsychology, 2022, , 1-8.	0.8	3
179	Lewy bodies are incidental in essential tremor. Parkinsonism and Related Disorders, 2016, 26, 81.	1.1	2
180	Do Parkinson disease subject and caregiver-reported Epworth sleepiness scale reponses correlate?. Clinical Neurology and Neurosurgery, 2020, 192, 105728.	0.6	2

#	Article	IF	CITATIONS
181	Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2021, 80, 1603-1612.	1.2	2
182	Predictive modeling of spread in adultâ€onset isolated dystonia: Key properties and effect of tremor inclusion. European Journal of Neurology, 2021, 28, 3999-4009.	1.7	2
183	Correlation Between the Movement Disorder Society's Unified Parkinson's Disease Rating Scale and Nonmotor Scales in Patients with Parkinson's Disease. Innovations in Clinical Neuroscience, 2019, 16, 27-29.	0.1	2
184	Mild cognitive impairment in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S81-S82.	1.1	1
185	Clinical Features of Patients with Concomitant Parkinson's Disease and Progressive Supranuclear Palsy Pathology. Movement Disorders Clinical Practice, 2015, 2, 33-38.	0.8	1
186	Are Clinical Certainty Ratings Helpful in the Diagnosis of Parkinson's Disease?. Movement Disorders Clinical Practice, 2018, 5, 165-170.	0.8	1
187	Sports-Related Task-Specific Dystonia: The Yips. Medical Psychiatry, 2006, , 209-217.	0.2	1
188	Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease: An Updated Clinicopathologic Study. Neurology: Clinical Practice, 2021, 11, e414-e421.	0.8	1
189	Assessing medication role on neuropathological findings in Parkinson's disease. Movement Disorders, 2016, 31, 613-614.	2.2	0
190	The association between vertebrobasilar dolichoectasia and hemifacial spasm: Historical perspective. Parkinsonism and Related Disorders, 2017, 38, 97.	1.1	0
191	High specificity and sensitivity of olfactory bulb synucleinopathy for Lewy body disorders. FASEB Journal, 2008, 22, 58.8.	0.2	0
192	Sports-related task-specific dystonia: The yips. , 2012, , 212-220.		0
193	The science of the yips. , 2017, , 369-379.		0